For research use only. Not for therapeutic Use.
Rivoglitazone is a thiazolidinedione-derivative PPARγ agonist for the research of type 2 diabetes mellitus.
| Catalog Number | M045082 |
| CAS Number | 185428-18-6 |
| Synonyms | 5-[[4-[(6-methoxy-1-methylbenzimidazol-2-yl)methoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione |
| Molecular Formula | C20H19N3O4S |
| Purity | ≥95% |
| InChI | InChI=1S/C20H19N3O4S/c1-23-16-10-14(26-2)7-8-15(16)21-18(23)11-27-13-5-3-12(4-6-13)9-17-19(24)22-20(25)28-17/h3-8,10,17H,9,11H2,1-2H3,(H,22,24,25) |
| InChIKey | XMSXOLDPMGMWTH-UHFFFAOYSA-N |
| SMILES | CN1C2=C(C=CC(=C2)OC)N=C1COC3=CC=C(C=C3)CC4C(=O)NC(=O)S4 |
| Reference | [1]. Kanda S, Nakashima R, Takahashi K, et al. Potent antidiabetic effects of rivoglitazone, a novel peroxisome proliferator-activated receptor-gamma agonist, in obese diabetic rodent models. J Pharmacol Sci. 2009;111(2):155-166. [2]. Uchiyama M, Iwabuchi H, Tsuruta F, et al. Pharmacokinetics, metabolism, and disposition of rivoglitazone, a novel peroxisome proliferator-activated receptor γ agonist, in rats and monkeys. Drug Metab Dispos. 2011;39(4):653-666. |
